Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes

Drug Metabolism and Disposition

Volumn 40, Issue 9, 2012, Pages 1757-1764

  Xing, Jie ^a,b   Kirby, Brian J ^a   Whittington, Dale ^a   Wan, Yakun ^c   Goodlett, David R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SHANDONG UNIVERSITY   (China)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIMALARIAL AGENT; ARTEMISININ; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DIHYDROARTEMISININ; GLUCURONOSYLTRANSFERASE; MESSENGER RNA; RIFAMPICIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DRUG INTERACTION; DRUG EXPOSURE; DRUG INTERACTION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; EVALUATION; HUMAN; HUMAN CELL; IC 50; LIVER CELL; LIVER MICROSOME; PREDICTION; PRIMARY CELL CULTURE; PRIORITY JOURNAL;

ANTIMALARIALS; ARTEMISININS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HEPATOCYTES; HUMANS; KINETICS; LIVER; MICROSOMES, LIVER; MODELS, BIOLOGICAL; OXIDOREDUCTASES, N-DEMETHYLATING; PRIMARY CELL CULTURE; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 84865192528     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045765     Document Type: Article

References (30)

1. Ashton M, Gordi T, Trinh NH, Nguyen VH, Nguyen DS, Nguyen TN, Dinh XH, Johansson M, and Le DC (1998b) Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. Biopharm Drug Dispos 19:245-250. (Pubitemid 28218419)
2. Ashton M, Hai TN, Sy ND, Huong DX, Van Huong N, Niêu NT, and Công LD (1998a) Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos 26:25-27. (Pubitemid 28071320)
3. Asimus S, Elsherbiny D, Hai TN, Jansson B, Huong NV, Petzold MG, Simonsson US, and Ashton M (2007) Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol 21:307-316. (Pubitemid 46800472)
4. Asimus S, Hai TN, Van Huong N, and Ashton M (2008) Artemisinin and CYP2A6 activity in healthy subjects. Eur J Clin Pharmacol 64:283-292.
5. Bapiro TE, Egnell AC, Hasler JA, and Masimirembwa CM (2001) Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 29:30-35. (Pubitemid 32041676)
6. Bapiro TE, Sayi J, Hasler JA, Jande M, Rimoy G, Masselle A, and Masimirembwa CM (2005) Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur J Clin Pharmacol 61:755-761. (Pubitemid 41674262)
7. Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF, and Eichelbaum M (2005) Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 67:1954-1965. (Pubitemid 41007777)
8. Chinh NT, Quang NN, Thanh NX, Dai B, Geue JP, Addison RS, Travers T, and Edstein MD (2009) Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Antimicrob Agents Chemother 53:828-831.
9. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, and von Seidlein L (2010) Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 8:272-280.
10. Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, and Simonsson US (2008) A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn 35:203-217.
11. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
12. Falade CO, Ogundele AO, Yusuf BO, Ademowo OG, and Ladipo SM (2008) High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Trop Med Int Health 13:635-643. (Pubitemid 351561605)
13. Gordi T, Xie R, and Jusko WJ (2005) Semi-mechanistic pharmacokinetic/ pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol 60:594-604. (Pubitemid 41705378)
14. Gautam A, Ahmed T, Batra V, and Paliwal J (2009) Pharmacokinetics and pharmacodynamics of endoperoxide antimalarials. Curr Drug Metab 10:289-306.
15. Hien TT, Hanpithakpong W, Truong NT, Dung NT, Toi PV, Farrar J, Lindegardh N, Tarning J, and Ashton M (2011) Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study. Clin Ther 33:644-654.
16. Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, Thu le TA, Hung NC, Pirmohamed M, et al. (2002) Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos 30:1005-1012.
17. Kenny JR, Chen L, McGinnity DF, Grime K, Shakesheff KM, Thomson B, and Riley R (2008) Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies. Xenobiotica 38:1500-1517.
18. Köhle C and Bock KW (2009) Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 77:689-699.
19. Li XQ, Björkman A, Andersson TB, Gustafsson LL, and Masimirembwa CM (2003) Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59:429-442. (Pubitemid 37214951)
20. McGinnity DF, Berry AJ, Kenny JR, Grime K, and Riley RJ (2006) Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 34:1291-1300. (Pubitemid 44079869)
21. Mihara K, Svensson US, Tybring G, Hai TN, Bertilsson L, and Ashton M (1999) Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19. Fundam Clin Pharmacol 13:671-675. (Pubitemid 30041854)
22. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348. (Pubitemid 41832613)
23. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255. (Pubitemid 46148737)
24. Pérez G, Tabares B, Jover R, Gómez-Lechón MJ, and Castell JV (2003) Semi-automatic quantitative RT-PCR to measure CYP induction by drugs in human hepatocytes. Toxicol In Vitro 17:643-649.
25. Simonsson US, Jansson B, Hai TN, Huong DX, Tybring G, and Ashton M (2003) Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 74:32-43. (Pubitemid 36776174)
26. Simonsson US, Lindell M, Raffalli-Mathieu F, Lannerbro A, Honkakoski P, and Lang MA (2006) In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin. Eur J Clin Invest 36:647-653. (Pubitemid 44213832)
27. Svensson US, Ashton M, Trinh NH, Bertilsson L, Dinh XH, Nguyen VH, Nguyen TN, Nguyen DS, Lykkesfeldt J, and Le DC (1998) Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 64:160-167. (Pubitemid 28423851)
28. Svensson US and Ashton M (1999) Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 48:528-535. (Pubitemid 29454233)
29. Westerink WM and Schoonen WG (2007) Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 21:1581-1591. (Pubitemid 350103536)
30. White NJ (2004) Antimalarial drug resistance. J Clin Invest 113:1084-1092.